Almac
Almac Group, often referred to simply as Almac, is a leading global contract development and manufacturing organisation headquartered in the United States. Established in 2004, Almac has expanded its operational footprint across key regions, including Europe and Asia, solidifying its presence in the pharmaceutical and biotechnology sectors. Specialising in drug development, clinical trial services, and commercial manufacturing, Almac distinguishes itself through its innovative solutions and commitment to quality. The company has achieved significant milestones, including the successful launch of numerous life-saving therapies, positioning itself as a trusted partner for clients in the healthcare industry. With a strong emphasis on customer collaboration and cutting-edge technology, Almac continues to enhance its market position, making a notable impact on the global landscape of drug development and manufacturing.
DitchCarbon Score
How does Almac's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Almac's score of 36 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Almac's reported carbon emissions
In 2023, Almac reported total carbon emissions of approximately 12728000 kg CO2e for Scope 1 and 17434000 kg CO2e for Scope 2, alongside a significant Scope 3 emission total of about 133895000 kg CO2e. This reflects a comprehensive approach to emissions reporting, covering all relevant scopes. Almac has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 50% by 2030, using 2019 as the baseline year. This target underscores their commitment to significant emissions reductions in the near term. Additionally, Almac has committed to achieving net-zero emissions across all scopes by 2050, aligning with industry standards for climate action. The company’s emissions data indicates a proactive stance in addressing climate change, with a focus on both immediate and long-term reduction strategies. Almac's efforts are particularly relevant in the context of the pharmaceuticals and biotechnology sector, where sustainability practices are increasingly critical.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 32,159,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,404,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Almac is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
